Arvinas Inc. (ARVN) Prices 5.714M Share Common Offering at $70/Sh

Pre-Open Stock Movers 12/15: (PRVL) (OCX) (MDWD) Higher; (MIRM) (SNOW) (OCUL) Lower (more...)

Today's Pre-Open Stock Movers

Prevail Therapeutics Inc. (NASDAQ: PRVL) 84.6% HIGHER; Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash... More

Arvinas Inc. (ARVN) PT Raised to $123 at Citi

Citi analyst Yigal Nochomovitz raised the price target on Arvinas Inc. (NASDAQ: ARVN) to $123.00 (from $43.00) while maintaining a Buy rating.... More

Arvinas Inc. (ARVN) IV elevated amid wide price movement

Arvinas Inc. (NASDAQ: ARVN) 30-day option implied volatility is at 144; compared to its 52-week range of 71 to 181 after sharp rally amid prostate and breast cancer treatment headlines.

After-Hours Stock Movers 12/14: (MDWD) (ARVN) (IVAC) Higher; (OCUL) (EAF) (ZIOP) Lower (more...)

Today's After-Hours Stock Movers

MediWound Ltd. (Nasdaq: MDWD) 25% HIGHER; announced it has further expanded its NexoBrid® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval,... More

Arvinas (ARVN) Gains Despite $250M Stock Offering

Arvinas, Inc. (Nasdaq: ARVN) is trading 3.4% higher after-hours despite announcing an underwritten public offering of $250.0 million of its common stock. Shares rose 95% today on positive clinical data for its PROTAC protein degraders ARV-471 and ARV-110.

Arvinas Inc. (ARVN) to Offer $250M in Common Stock

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced that it is commencing an underwritten public offering of $250.0 million of its common stock. In addition, Arvinas... More

Arvinas Inc. (ARVN) files automatic mixed securities shelf

Arvinas Inc. (NASDAQ: ARVN) files automatic mixed securities shelf

Arvinas Inc. (ARVN) PT Raised to $129 at Goldman Sachs, Following Clinical Update

Goldman Sachs analyst Terence Flynn raised the price target on Arvinas Inc. (NASDAQ: ARVN) to $129.00 (from $78.00) while maintaining a Buy rating.

Oppenheimer Upgrades Arvinas Inc. (ARVN) to Outperform, Following Clinical Update

Oppenheimer analyst Mark Breidenbach upgraded Arvinas Inc. (NASDAQ: ARVN) from Perform to Outperform.

For an analyst ratings summary and ratings history on Arvinas Inc. click here. For more ratings news on Arvinas Inc. click here.

Shares of Arvinas Inc. closed at $29.93 yesterday.

Arvinas Inc. (ARVN) PT Raised to $100 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the price target on Arvinas Inc. (NASDAQ: ARVN) to $100.00 (from $60.00) while maintaining a Buy rating.

Arvinas Inc. (ARVN) PT Raised to 'Street High' $114 at BMO Capital

BMO Capital analyst George Farmer raised the price target on Arvinas Inc. (NASDAQ: ARVN) to a 'Street High' $114.00 (from $62.00) while maintaining an Outperform rating.

The analyst commented, "We believe interim results from clinical trials strongly support the promise of ARVNs PROTAC drug... More

Arvinas Inc. (ARVN) PT Raised to 'Street High' $93 at Wedbush

Wedbush analyst Robert Driscoll raised the price target on Arvinas Inc. (NASDAQ: ARVN) to a 'Street High' $93.00 (from $62.00) while maintaining an Outperform rating.

Pre-Open Stock Movers 12/14: (ARVN) (VERU) (ALXN) Higher; (ARPO) (SPCE) (AZN) Lower (more...)

Today's Pre-Open Stock Movers:

Arvinas, Inc. (Nasdaq: ARVN) 143.7% HIGHER; announced clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110. For ARV-471, interim Phase 1 data show potential for best-in-class safety and tolerability, estrogen receptor (ER) degradation superior to that previously reported for the current standard of care agent (fulvestrant), and robust efficacy signals in heavily pretreated patients with locally advanced or metastatic ER positive / HER2 negative (ER+/HER2-) breast cancer. The efficacy signals include one Response Evaluation Criteria in Solid Tumors (RECIST) confirmed partial response... More

Arvinas Inc. (ARVN) Climbs 150%

Arvinas Inc. (NASDAQ: ARVN) Climbs 150%

Arvinas Inc. (ARVN) Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC Protein Degraders ARV-471 and ARV-110

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110. For ARV-471, interim Phase 1 data show potential for best-in-class safety and tolerability, estrogen receptor (ER) degradation superior to that previously reported for the current standard of care agent (fulvestrant), and robust efficacy signals in heavily pretreated patients with locally advanced or metastatic ER positive / HER2 negative (ER+/HER2-) breast cancer. The efficacy signals include one Response... More